{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:12:45Z","timestamp":1793301165794,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["ECF 1111136"],"award-info":[{"award-number":["ECF 1111136"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.schres.2018.05.046","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T09:08:44Z","timestamp":1528103324000},"page":"10-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"special_numbering":"C","title":["Prescriber and institutional barriers and facilitators of clozapine use: A systematic review"],"prefix":"10.1016","volume":"201","author":[{"given":"H\u00e9l\u00e8ne","family":"Verdoux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9lia","family":"Quiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-9216","authenticated-orcid":false,"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2018.05.046_bb0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/acps.12742","article-title":"International trends in clozapine use: a study in 17 countries","volume":"136","author":"Bachmann","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2018.05.046_bb0010","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2018.05.046_bb0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/acps.12327","article-title":"The practical management of refractory schizophrenia\u2013the Maudsley Treatment REview and Assessment Team service approach","volume":"130","author":"Beck","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2018.05.046_bb0020","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4088\/JCP.10m06497","article-title":"The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state","volume":"73","author":"Berkowitz","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2018.05.046_bb0025","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.euroneuro.2014.11.022","article-title":"Capillary compared to venous blood sampling in clozapine treatment: patients and healthcare practitioners experiences with a point-of-care device","volume":"25","author":"Bogers","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2018.05.046_bb0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JCP.0000000000000478","article-title":"Clozapine underutilization in the treatment of schizophrenia. How can clozapine prescription rates be improved?","volume":"36","author":"Bogers","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2018.05.046_bb0035","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1176\/appi.ps.201500493","article-title":"An initiative to improve clozapine prescribing in New York State","volume":"67","author":"Carruthers","year":"2016","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2018.05.046_bb0040","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1192\/pb.29.10.377","article-title":"Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units","volume":"29","author":"Cirulli","year":"2005","journal-title":"Psychiatr. Bull."},{"key":"10.1016\/j.schres.2018.05.046_bb0045","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/acps.12294","article-title":"Prescribers fear as a major side-effect of clozapine","volume":"30","author":"Cohen","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2018.05.046_bb0050","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1192\/pb.bp.106.013144","article-title":"Clozapine: national review of postcode prescribing","volume":"31","author":"Downs","year":"2007","journal-title":"Psychiatr. Bull."},{"key":"10.1016\/j.schres.2018.05.046_bb0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0447.2012.01863.x","article-title":"Optimizing clozapine through clinical decision making","volume":"126","author":"Falzer","year":"2012","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2018.05.046_bb0060","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1055\/s-0035-1554713","article-title":"Increasing clozapine dispensing trends in Queensland, Australia 2004\u20132013","volume":"48","author":"Forrester","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2018.05.046_bb0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1176\/appi.ap.11090159","article-title":"Training in a clozapine clinic for psychiatry residents: a plea and suggestions for implementation","volume":"37","author":"Freudenreich","year":"2013","journal-title":"Acad. Psychiatry"},{"key":"10.1016\/j.schres.2018.05.046_bb0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/acps.12193","article-title":"Practitioner attitudes to clozapine initiation","volume":"130","author":"Gee","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2018.05.046_bb0075","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1176\/appi.ps.201500506","article-title":"Organizational characteristics of veterans affairs clinics with high and low utilization of clozapine","volume":"67","author":"Goren","year":"2016","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2018.05.046_bb0080","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1176\/appi.ps.201500507","article-title":"The business case for expanded clozapine utilization","volume":"67","author":"Goren","year":"2016","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2018.05.046_bb0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ajp.2015.09.013","article-title":"Prescription practices and attitude of psychiatrists towards clozapine: a survey of psychiatrists from India","volume":"18","author":"Grover","year":"2015","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.schres.2018.05.046_bb0090","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11096-010-9398-5","article-title":"Patterns of clozapine prescribing in a mental health service in New Zealand","volume":"32","author":"Harrison","year":"2010","journal-title":"Pharm. World Sci."},{"key":"10.1016\/j.schres.2018.05.046_bb0095","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2018.05.046_bb0100","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1600-0447.2011.01711.x","article-title":"A user' guide to clozapine","volume":"23","author":"Kane","year":"2011","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2018.05.046_bb0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","article-title":"The social and economic burden of treatment-resistant schizophrenia: a systematic literature review","volume":"29","author":"Kennedy","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2018.05.046_bb0110","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/acps.12700","article-title":"The impact of clozapine on hospital use: a systematic review and meta-analysis","volume":"135","author":"Land","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2018.05.046_bb0115","first-page":"182","article-title":"Psychiatrists' psychotropic drug prescription preferences for themselves or their family members","volume":"24","author":"Latas","year":"2012","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.schres.2018.05.046_bb0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3371\/CSRP.LAWY.012513","article-title":"Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Quebec","volume":"7","author":"Latimer","year":"2013","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.schres.2018.05.046_bb0125","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00005053-200106000-00005","article-title":"The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia","volume":"189","author":"Leslie","year":"2001","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.schres.2018.05.046_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.schres.2018.05.046_bb0135","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/0269881108100320","article-title":"Psychiatrists' attitude towards and knowledge of clozapine treatment","volume":"24","author":"Nielsen","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2018.05.046_bb0140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0447.2011.01710.x","article-title":"Optimizing clozapine treatment","volume":"123","author":"Nielsen","year":"2011","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2018.05.046_bb0145","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.euroneuro.2012.03.003","article-title":"Geographical and temporal variations in clozapine prescription for schizophrenia","volume":"22","author":"Nielsen","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2018.05.046_bb0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40263-016-0311-1","article-title":"Worldwide differences in regulations of clozapine use","volume":"30","author":"Nielsen","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2018.05.046_bb0155","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ps.201500324","article-title":"Clozapine for schizophrenia: state variation in evidence-based practice","volume":"67","author":"Olfson","year":"2016","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2018.05.046_bb0160","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1192\/pb.30.11.410","article-title":"Survey of clozapine use by consultant old age psychiatrists","volume":"30","author":"Paranthaman","year":"2006","journal-title":"Psychiatr. Bull."},{"key":"10.1016\/j.schres.2018.05.046_bb0165","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.euroneuro.2014.01.014","article-title":"Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales","volume":"24","author":"Patel","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2018.05.046_bb0170","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1192\/pb.24.11.420","article-title":"Postcode prescribing in psychiatry. Clozapine in an English county","volume":"24","author":"Purcell","year":"2000","journal-title":"Psychiatr. Bull."},{"key":"10.1016\/j.schres.2018.05.046_bb0175","first-page":"739","article-title":"Clozapine use by state programs: public mental health systems respond to a new medication","volume":"44","author":"Reid","year":"1993","journal-title":"Hosp. Community Psychiatry"},{"key":"10.1016\/j.schres.2018.05.046_bb0180","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4103\/0019-5545.55097","article-title":"Prescribing practices of clozapine in India: results of an opinion survey of psychiatrists","volume":"51","author":"Shrivastava","year":"2009","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.schres.2018.05.046_bb0185","doi-asserted-by":"crossref","first-page":"99","DOI":"10.9758\/cpn.2012.10.2.99","article-title":"Use of clozapine for the treatment of schizophrenia: findings of the 2006 research on the China psychotropic prescription studies","volume":"10","author":"Si","year":"2012","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.schres.2018.05.046_bb0190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1590\/0101-60830000000069","article-title":"Patterns of clozapine and other antipsychotics prescriptions in patients with treatment-resistant schizophrenia in community mental health centers in Sao Paulo, Brazil","volume":"42","author":"Silveira","year":"2015","journal-title":"Arch. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2018.05.046_bb0195","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis","volume":"62","author":"Siskind","year":"2017","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.schres.2018.05.046_bb0200","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S2045796016000305","article-title":"Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis","volume":"26","author":"Siskind","year":"2017","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.schres.2018.05.046_bb0205","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1176\/appi.ps.201300180","article-title":"Geographic and clinical variation in clozapine use in the United States","volume":"65","author":"Stroup","year":"2014","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2018.05.046_bb0210","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1176\/appi.ajp.2015.15030332","article-title":"Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia","volume":"173","author":"Stroup","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2018.05.046_bb0215","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.schres.2011.09.016","article-title":"Treatment resistant schizophrenia and response to antipsychotics: a review","volume":"133","author":"Suzuki","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.05.046_bb0220","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/appi.ps.201600041","article-title":"Prescribing of clozapine and antipsychotic polypharmacy for schizophrenia in a large medicaid program","volume":"68","author":"Tang","year":"2017","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2018.05.046_bb0225","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0042-116947","article-title":"Time to initiation of clozapine treatment in children and adolescents with early-onset schizophrenia","volume":"49","author":"Trinczek","year":"2016","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2018.05.046_bb0230","series-title":"Therapeutic Advances in Psychopharmacology","first-page":"88","article-title":"Clozapine prescribing in the UK: views and experience of consultant psychiatrists","volume":"5","author":"Tungaraza","year":"2015"},{"key":"10.1016\/j.schres.2018.05.046_bb0235","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000063669","article-title":"Impact on Thai psychiatrists of passive dissemination of a clinical practice guideline on prescribing attitudes in treatment-resistant schizophrenia","volume":"45","author":"Udomratn","year":"2002","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.schres.2018.05.046_bb0240","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1600-0447.2011.01745.x","article-title":"A pharmacoepidemiological analysis of clozapine use in a region of Australia","volume":"24","author":"Vella","year":"2011","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2018.05.046_bb0245","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/acps.12344","article-title":"Clozapine use pattern in persons with and without treatment for Parkinson's disease in real-world conditions: a naturalistic study in a community-based sample","volume":"30","author":"Verdoux","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2018.05.046_bb0250","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/acps.12554","article-title":"Geographical disparities in prescription practices of lithium and clozapine: a community-based study","volume":"133","author":"Verdoux","year":"2016","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2018.05.046_bb0255","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2753.2008.01032.x","article-title":"Impact of audit and feedback on antipsychotic prescribing in schizophrenia","volume":"15","author":"Wheeler","year":"2009","journal-title":"J. Eval. Clin. Pract."},{"key":"10.1016\/j.schres.2018.05.046_bb0260","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0269881108093588","article-title":"Outcomes for schizophrenia patients with clozapine treatment: how good does it get?","volume":"23","author":"Wheeler","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2018.05.046_bb0265","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1017\/S0955603600002270","article-title":"Continuation of clozapine treatment: practice makes perfect","volume":"27","author":"Whiskey","year":"2003","journal-title":"Psychiatr. Bull."},{"key":"10.1016\/j.schres.2018.05.046_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066154","article-title":"Use of clozapine in older Asian patients with schizophrenia between 2001 and 2009","volume":"8","author":"Xiang","year":"2013","journal-title":"PLoS One"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418303116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418303116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T20:05:52Z","timestamp":1661371552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996418303116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":54,"alternative-id":["S0920996418303116"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2018.05.046","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescriber and institutional barriers and facilitators of clozapine use: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2018.05.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}